Berlin-based AMBOSS, a medical education and clinical decision-making platform, has secured €240 million in funding to expand its global reach. The company aims to extend its services to nurses and other healthcare professionals while continuing to support medical students and clinicians. The funding round includes participation from new long-term investors, reflecting continued interest in digital healthcare solutions. AMBOSS has also restructured as a European stock corporation (SE) to facilitate future growth.
The company has previously raised significant investment to strengthen its offerings. Over the years, it has expanded into international markets, gaining a strong foothold in the United States. Its influence extends to medical students, with a large share of US-based learners depending on the platform for exam preparation. The latest investment follows the company’s recent acquisitions, such as Novaheal and NEJM Knowledge+, which have helped diversify its portfolio to include nursing and board exam preparation.
Who are the new investors?
AMBOSS has attracted new investors, including KIRKBI, M&G Investments, and Lightrock, in addition to backing from existing shareholders. This financial support is expected to fuel further expansion and technological advancements. The company’s restructuring into a European stock corporation is seen as a move to enhance its governance and facilitate long-term investment strategies.
“We have followed AMBOSS’ impressive growth journey, from its successful US expansion to its strong focus on innovation. Its unique platform is becoming a vital tool for both medical students and healthcare professionals, supporting learning and decision-making at every stage,” said Peter Bason, Head of Private Capital at KIRKBI.
How will the funding be used?
AMBOSS will allocate the newly raised capital toward technological improvements and further expansion into new markets. The company plans to enhance its platform with more tools for healthcare professionals, addressing clinical decision-making and medical education needs. Recent acquisitions indicate a strategy focused on broadening its user base beyond medical students to include other healthcare workers.
“Additional funds will go into further investment in technology and new market segments. Selective acquisitions will also continue to be part of our strategy,” said co-founder and co-CEO Benedikt Hochkirchen.
AMBOSS currently serves over one million professionals across 180 countries. It integrates medical expertise with technology, offering evidence-based recommendations that assist physicians in clinical decision-making. In Germany, the platform is used in half of all inpatient treatments, while in the US, a significant percentage of medical students rely on it for exam preparation.
The role of AI in AMBOSS’ platform continues to grow, with a focus on improving the reliability and efficiency of healthcare education and decision-making. The company emphasizes that technology serves to support healthcare professionals rather than replace them. As the platform develops, its influence is likely to extend further within medical and healthcare training globally.
With this investment, AMBOSS is positioned to strengthen its presence in the medical education sector while exploring additional healthcare fields. Its long-term goal appears to be an eventual public offering, supported by investors with evergreen funds. The company’s approach of combining acquisitions with organic growth signals an effort to establish itself as a key player in digital healthcare education. Future developments will determine the extent of its impact in assisting medical professionals worldwide.
